MNMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MNMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Mind Medicine's quarterly cash, cash equivalents, marketable securities increased from Dec. 2023 ($99.70 Mil) to Mar. 2024 ($252.33 Mil) but then stayed the same from Mar. 2024 ($252.33 Mil) to Jun. 2024 ($243.13 Mil).
Mind Medicine's annual cash, cash equivalents, marketable securities increased from Dec. 2021 ($133.54 Mil) to Dec. 2022 ($142.14 Mil) but then declined from Dec. 2022 ($142.14 Mil) to Dec. 2023 ($99.70 Mil).
The historical data trend for Mind Medicine's Cash, Cash Equivalents, Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mind Medicine Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Cash, Cash Equivalents, Marketable Securities | 80.09 | 133.54 | 142.14 | 99.70 |
Mind Medicine Quarterly Data | |||||||||||||||||||
Sep19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Cash, Cash Equivalents, Marketable Securities | Get a 7-Day Free Trial | 116.90 | 117.70 | 99.70 | 252.33 | 243.13 |
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.
Mind Medicine (NAS:MNMD) Cash, Cash Equivalents, Marketable Securities Explanation
Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Thank you for viewing the detailed overview of Mind Medicine's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.
Mark Sullivan | officer: Chief Legal Officer | 1000 BISHOPS GATE BOULEVARD, SUITE 300, MOUNT LAUREL NJ 08054 |
Robert Barrow | director, officer: Chief Executive Officer | C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007 |
Dan Karlin | officer: Chief Medical Officer | C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007 |
Carrie Liao | officer: VP, Controller&Acct Principal | C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007 |
David W Gryska | director | 749 N MARY AVE, SUNNYVALE CA 94085 |
Schond L. Greenway | officer: Chief Financial Officer | C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850 |
Carol A Vallone | director | 490 SUMMER STREET, MANCHESTER MA 01944 |
Andreas Krebs | director | 5 GIRALDA FARMS, MADISON NJ 07940 |
Suzanne Louise Bruhn | director | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746 |
Roger Crystal | director | 445 PARK AVE, 10TH FL., NEW YORK NY 10022 |
Cynthia W. Hu | officer: Chief Legal Officer&Secretary | 6440 WINDERMERE, NORTH BETHESDA MD 20852 |
Brigid Makes | director | 20245 SW 95TH AVENUE, TUALATIN OR 97062 |
Sarah Y Vinson | director | C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007 |
Stephen L Hurst | director | C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007 |
Miri Halperin Wernli | director, officer: Executive President | C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007 |
From GuruFocus
By Business Wire • 03-11-2024
By GuruFocus Research • 08-16-2024
By Business Wire • 08-13-2024
By Business Wire • 04-01-2024
By Business Wire • 06-21-2024
By Business Wire • 09-09-2024
By Business Wire • 08-09-2024
By Business Wire • 05-28-2024
By Business Wire • 08-06-2024
By GuruFocus Research • 08-16-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.